GlassScriptPhysician profile
Pramod Vadlamani
NPI 1336204684
$4,299.06
in general payments reported to CMS, 2019-2025
33 companies · $368 in 2025
The $368 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $175 · 2021: $704 · 2022: $1,091 · 2023: $938 · 2024: $553 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,664 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,663.64 |
| Education | $194.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,368.14 | 2019-2025 | Imfinzi, Lynparza |
| Incyte Corporation | $382.76 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $343.18 | 2021-2024 | Opdivo |
| Janssen Biotech, INC. | $290.85 | 2022-2025 | Carvykti, Rybrevant, Darzalex |
| Lilly USA, LLC | $284.72 | 2019-2023 | Verzenio, Retevmo, Jaypirca |
| Eisai INC. | $224.96 | 2022-2025 | |
| Seagen INC. | $180.10 | 2021-2023 | Padcev |
| Pharmacyclics LLC, An Abbvie Company | $142.12 | 2023 | Imbruvica |
| Genzyme Corporation | $139.18 | 2019-2021 | |
| Kyowa Kirin, INC. | $114.00 | 2022 | |
| Pfizer INC. | $107.51 | 2019-2023 | |
| Abbvie INC. | $105.26 | 2023 | Epkinly |
| Karyopharm Therapeutics INC. | $102.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $64.04 | 2019-2023 | |
| Amgen INC. | $53.95 | 2019-2023 | Kyprolis, Lumakras |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $48.20 | 2023 | Keytruda, Welireg, Lynparza |
| Emd Serono, INC. | $36.80 | 2023 | Bavencio |
| Exelixis INC. | $29.91 | 2019-2022 | |
| Gilead Sciences, INC. | $29.48 | 2021-2022 | |
| Celgene Corporation | $27.11 | 2022-2023 | Pomalyst |
| Mirati Therapeutics, INC. | $26.26 | 2023 | Krazati |
| Caris Mpi, INC. | $21.56 | 2025 | Mi Cancer Seek |
| Pharmacosmos Therapeutics INC. | $19.61 | 2023 | Monoferric |
| Beigene USA, INC. | $19.35 | 2023 | Brukinsa |
| Daiichi Sankyo INC. | $19.28 | 2025 | Datroway |
| Argenx US, INC. | $19.22 | 2023 | Vyvgart |
| Sobi, INC | $17.88 | 2023 | |
| Myriad Genetic Laboratories, INC. | $15.31 | 2023 | Precisetumor |
| Regeneron Healthcare Solutions, INC. | $14.43 | 2022 | |
| Astellas Pharma US INC | $13.85 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.46 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.01 | 2022 | |
| Genentech USA, INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pramod Vadlamani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.